

## Change in Nomination Committee prior to AGM 2023 in SynAct Pharma

**SynAct Pharma AB (publ) ("SynAct") announced today that the composition of the Nomination Committee prior to the Annual General Meeting on 25 May 2023 has changed as a result of a change of ownership.**

The composition of the Nomination Committee prior to the 2023 Annual General Meeting was announced in a press release on 21 October 2022. Thomas von Koch has in December 2022 through the company TomEnterprise Public Capital AB subscribed for shares corresponding to approximately 3.8 percent of the total number of shares and votes in the company and thereby become a larger shareholder in SynAct. As a result of the change of ownership, the composition of the Nomination Committee, in accordance with the instructions for the Nomination Committee adopted by the Annual General Meeting, has changed by Steen Christensen (appointed by Next Stage Ventures ApS) leaving the Nomination Committee and Per Colleen (appointed by TomEnterprise Public Capital AB) entered as a new member of the Nomination Committee.

Following the change, the Nomination Committee for the 2023 Annual General Meeting consists of the following persons:

- Niels Ankerstjerne Sloth, appointed by Bioinvest ApS;
- Per Colleen, appointed by TomEnterprise Public Capital AB;
- Jens Bager, appointed by GL Capital AB; and
- Torbjørn Bjerke, Chairman of the Board.

Jens Bager remains as Chairman of the Nomination Committee.

The Nomination Committee's tasks for the Annual General Meeting are to propose a Chairman for the Annual General Meeting, election of Chairman and other Board members, fees to the Board of Directors, divided between the Chairman and other members, and any fees for committee work and election of auditor and fees to the auditor. Finally, the Nomination Committee will propose principles for appointing the Nomination Committee (if the Nomination Committee considers that the current principles and instructions should be updated).

Shareholders are welcome to submit their proposals and views to the Nomination Committee to SynAct Pharma AB, Att: Nomination Committee, Scheelevägen 2, 223 63 Lund, or by e-mail to [valberedning@synactpharma.com](mailto:valberedning@synactpharma.com). To ensure that proposals can be considered by the Nomination Committee, proposals shall be submitted in due time before the Annual General Meeting, but no later than 31 January 2023.

The Nomination Committee's proposals will be announced in the notice to the Annual General Meeting 2023 and on SynAct's website.

*The information was submitted for publication, through the agency of the contact persons set out below, on 22 December 2022 at 07:00 a.m. CET.*

**For further information about SynAct Pharma AB, please contact:****Jeppe Øvlesen**

CEO, SynAct Pharma AB

Phone: +45 28 44 75 67

Mail: [joo@synactpharma.com](mailto:joo@synactpharma.com)**Patrik Renblad**

CFO, SynAct Pharma AB

Phone: +46 707 47 97 68

Mail: [par@synactpharma.com](mailto:par@synactpharma.com)**About SynAct Pharma AB**

SynAct Pharma AB (publ) (Nasdaq Stockholm: SYNACT) conducts research and development in inflammatory diseases. The company has a platform technology based on a new class of drug candidates aimed at acute deterioration in chronic inflammatory diseases with the primary purpose of stimulating natural healing mechanisms. For more information: [www.synactpharma.com](http://www.synactpharma.com).

**Attachments**

[Change in Nomination Committee prior to AGM 2023 in SynAct Pharma](#)